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that can be managed successfully by erythropoiesis-stimulating agents (ESA) administration.
Aims: To investigate current practice of anemia management in hemodialysis patients and to
assess the appropriateness of anemia management by comparing observed practice to the Kidney
Disease Outcomes Quality Initiative (KDOQI) guideline recommendations.
Settings and design: The study was conducted at two hemodialysis centers in Riyadh, Saudi
Arabia. Data on anemia parameters, comorbidities, ESA dosing and iron supplementation were
collected. The data were collected for 7 months retrospectively from April to the end of May
2008 and prospectively from June to October 2008. Patients who were over 18 years of age with
ESRD undergoing hemodialysis were included. Patients were excluded if they have cancer or receiv-
ing chemotherapy or radiotherapy.
Results: Data were collected from 87 patients. Mean Hgb value for those patients was
11.16 ± 0.97 g/dL. Thirty-nine patients (45%) had mean Hgb values between 11.0 and 12.0 g/dLBox 376316, Riyadh 11335,
.A. Al-Aqeel).
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86 N.A. Al-Ageel et al.the target range recommended by KDOQI guideline. The mean weekly prescribed dose of erythro-
poietin was 8099 ± 5946 IU/Week (135 ± 99 IU/kg/Week). Information on ferritin concentrations
was available for 48 (55%) patients. The mean serum ferritin concentration for those patients was
693 ± 420.5 ng/mL. Fifty-two patients had transferrin saturation (TSAT) values recorded. The
mean TSAT value was 38.5 ± 19.7%. Conclusions: There is an opportunity to improve anemia
management in hemodialysis patients particularly thorough evaluation of causes of inadequate
response rate and better monitoring and management of iron status.
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The anemia of end stage renal disease (ESRD) is a common
and often severe complication that can be managed success-
fully by erythropoiesis-stimulating agents (ESA) administra-
tion (Schmid et al., 2010; Dowling, 2007; Lefebvre et al.,
2006; Leaf and Goldfarb, 2009).
A study screened 480 ESRD patients from six Arabian Gulf
countries including Saudi Arabia (Alsuwaida et al., 2007) and
found that one-third of the surveyed patients had suboptimal
hemoglobin (Hgb) levels and iron stores. The limitations of this
study were that it was a one day cross sectional study and the
data were limited to the available information without accessing
historical notes. The purpose of our study was to determine the
current practice of anemia management in hemodialysis pa-
tients over seven months. Furthermore, we assessed the appro-
priateness of anemia management by comparing observed
practice to an evidence based clinical guidelines, theKidneyDis-
ease Outcomes Quality Initiative (KDOQI) guidelines and prac-
tice recommendations (National Kidney Foundation, 2007).
2. Patients and methodology
The study was conducted at two hemodialysis centers. The ﬁrst
is the hemodialysis center at the King Khalid University Hos-
pital (KKUH) and the second is the Ministry of Health Centre,
Prince Salman Centre for Kidney Disease (PSC), both in
Riyadh, Saudi Arabia. All patients who were over 18 years
of age with ESRD undergoing hemodialysis were included.
Patients were excluded if they have cancer or are receiving che-
motherapy or radiotherapy. Data on anemia parameters,
erythropoietin dosing, iron supplementation, in addition to
demographic data were collected. The data were collected over
a 7 months period retrospectively from April to the end of
May 2008 and prospectively from June to October 2008.
Descriptive statistics and frequency distributions were com-
puted for all the variables. For continuous data independent
samples Student’s t-test or analysis of variance were conducted
to determine any signiﬁcant differences among groups as appro-
priate. Chi-square test was used for categorical data. Statistical
signiﬁcance was determined at a p-value lower than 0.05. All sta-
tistical analysis was performed using SPSS (version 15.00).
3. Results
3.1. Demographic and clinical characteristics of patient sample
Data were collected from 87 patients with a mean age of
50 ± 14 years. The majority of patients had been receiving
hemodialysis for two or more years. The most commonprimary cause of end stage renal failure was diabetic nephrop-
athy (22%). Hypertension was the most common comorbidity
(76%), followed by diabetes (36%), ischemic heart disease
(24%), and viral hepatitis (22%) (Table 1).
3.2. Hemoglobin level
The mean Hgb value was 11.16 ± 0.97 g/dL. Thirty-nine
patients (45%) had mean Hgb values between 11.0 and
12.0 g/dL the target range recommended by KDOQI guideline.
Twenty-six patients (30%) had mean Hgb values between 10.0
to 11.0 g/dL. Nine patients (10%) had mean Hgb values less
than 10 g/dL. Thirteen patients (15%) exceed the recom-
mended range (>12 g/dL). Fig. 1 shows the distribution of pa-
tients based on Hgb values in each hemodialysis center.3.3. Erythropoietin dose
The mean weekly prescribed dose of erythropoietin was
8099 ± 5946 IU/Week (135 ± 99 IU/kg/Week) (Table 2).
The distribution of mean erythropoietin dose in hemodialysis
patients from both centers is shown in Fig. 2. Fig. 3 illustrates
that the erythropoietin dose decreased with increasing Hgb
values. Erythropoietin was given by IV route at the end of dial-
ysis session which is the favored route of administration in
hemodialysis patients by KDOQI guideline.
3.4. Monitoring iron status
Out of 87 patients, 71 (81.6%) received iron replacement therapy
all of themvia the intravenous route. Informationon ferritin con-
centrations was available for 48 (55%) patients. Themean serum
ferritin concentration for those patientswas693 ± 420.5 ng/mL.
Fifty-two patients had transferrin saturation (TSAT) values re-
corded. The mean TSAT value was 38.5 ± 19.7%. Nineteen pa-
tients had both TSAT and ferritin recorded, of them 12 (63%)
were assessed as having adequate iron status, deﬁned byKDOQI
guideline as a serum ferritin concentration ofP200 ng/mLplus a
TSATvalue ofP20% (Table 3). Fig. 4 shows that the percentage
of patients who did not meet the recommended target for trans-
ferrin saturation is higher with mean hemoglobin values <11 g/
dL. Iron status monitoring test was performed monthly in PSC
and every three months in the KKUH.3.5. Patient characteristics associated with lower hemoglobin
concentrations
Factors such as albumin level and administration of intrave-
nous iron supplementation were investigated (Table 4) and it
Table 1 Characteristic of the study patients.
Characteristic Total (n= 87) KKUH (n= 38) PSC (n= 49)
Sex, n (%)
Male 38 (44) 14 (37) 24 (49)
Female 49 (56) 24 (63) 25 (51)
Age (years)
Mean ± SD 50.2 ± 14.3 48.76 ± 15.63 51.39 ± 13.2
Median (range) 55 (21–76) 50 (21–76) 54 (25–57)
Dry body weight (kg)
Mean ± SD 62.6 ± 14.5 61.5263 ± 12.4 63.4913 ± 16.6
Median (range) 68 (33–101) 65.25 (39–82) 62 (33–101)
Primary renal disease, n (%)
Diabetes nephropathy 19 (22) 6 (16) 13 (27)
Glomerulosclerosis 7 (8) 6 (16) 1 (2)
Glomerulonephritis 3 (3) 3 (8) –
Polycystic kidney disease 4 (5) 2 (5) 2 (4)
Unknown and other 25 (29) 17 (45) 8 (16)
Not recorded 29 (33) 4 (11) 25 (51)
Duration of dialysis (year) n (%)
0.5–0.99 20 (23) 8 (21.1) 12 (24.5)
1–1.9 31 (35.6) 10 (26.3) 21 (42.9)
P2 36 (41.4) 20 (52.6) 16 (32.7)
Co-morbidity, n (%)
Diabetes 31 (36) 12 (32) 19 (39)
Hypertension 66 (76) 24 (63) 42 (86)
Ischemic heart disease 21 (24) 6 (16) 15 (31)
Hepatitis 19 (22) 5 (13) 14 (29)
KKUH=King Khalid University Hospital, PSC = Prince Salman Centre for Kidney Disease.
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Figure 1 Percentage of patients by mean Hgb levels.
Appropriateness of anemia management in hemodialysis patients 87appears that females (0.460, p= 0.04) and those with low
albumin level (0.64, p= 0.016) have statistically signiﬁcant
lower Hgb levels.
4. Discussion
The current study differs from the Gulf Survey on Anemia
Management (GSAM 2005) study (Alsuwaida et al., 2007).
GSAM 2005 was a one day survey involving 480 patients from
six countries, whereas in our study data were obtained from 87
patients from one country over a period of 7 months. In both
surveys the most common primary cause of end stage renal
failure was diabetic nephropathy and hypertension was thecommon co-morbidity. Females represent 56% of our sample
vs 48% in GSAM. The mean Hgb in the current study
(11.16 g/dL) was slightly lower than GSAM mean of
11.45 g/dL. The percentage of patients with Hgb lower than
11 g/dL is higher in the current study (40% vs 34%), but the
percentage of patients with lower than 10 mg/dL is smaller
in our study (10% vs 16%). The two surveys, however, concur
on an important observation that anemia is unsatisfactorily
controlled in hemodialysis patients. This ﬁnding is not unique
to Saudi Arabia. The European Survey of Anemia Manage-
ment (ESAM) (Jacobs et al., 2005) was a one day randomized
survey conducted to assess anemia management in 8100 dialy-
sis patients from 12 countries, and demonstrated that only
Table 2 Erythropoietin dosing in the two dialysis units.
Total (n= 87) (SD) KKUH (n= 38) PSC (N= 49)
Mean dose (IU/Week) 8100 (5946.5) 7755 (5930) 8367 (6006)
Mean dose (IU/g/Week) 135 (99) 127.4 (91) 141 (106)
Median dose (IU/Week) 6286 6107 6357
Median dose (IU/kg/Week) 110 99 117
KKUH=King Khalid University Hospital, PSC = Prince Salman Centre for Kidney Disease.
Figure 2 Distribution of weekly erythropoietin dose between the two centers.
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Figure 3 Mean weekly prescribed erythropoietin dose by mean Hgb level.
88 N.A. Al-Ageel et al.66% of patients achieved Hgb level >11.0 g/dL. The Dialysis
Outcomes and Practice Patterns Study (DOPPS) (Locatelli
et al., 2004), a prospective observational study based on the
data collected from 4591 hemodialysis from ﬁve European
countries, found that only 53% of the patients achieved Hgb
level >11.0 g/dL.
The observed lower hemoglobin level in our study could be
attributed to a number of reasons. A crucial factor for achiev-
ing a satisfactory response to erythropoietin therapy is the ade-
quate iron status. The two primary tests used in the assessment
of iron status are serum ferritin and TSAT levels. Serum ferri-
tin concentration correlates well with total body iron storeswhile TSAT indicates iron supply for erythropoiesis. The
accurate determination of iron status in hemodialysis patients,
however, can be a challenging task. Both serum ferritin and
TSAT levels may be altered by factors that are unrelated to
iron metabolism. For instance, the chronic inﬂammatory state
associated with malnutrition and clinical or subclinical infec-
tions may increase serum ferritin levels that falsely suggest a
state of iron repletion (Coyne, 2006). Therefore, if ferritin lev-
els suggest replete iron stores whereas TSAT level suggests
insufﬁcient iron availability; investigations should be done to
exclude these factors. Falling to do so leads to a risk of misdi-
agnosing the patient with iron overload and place the patient
Table 3 Iron status in the two dialysis units using TSAT and serum ferritin level.
Iron status Total (n= 87) KKUH (n= 38) PSC (n= 49)
Iron replacement (%) 71 (81.6) 31 (81.6) 40 (81.6)
IV route (%) 71 (100) 31 (100) 40 (100)
Patients with recoded ferritin 48 (55.2) 34 (89.5) 14 (28.6)
Mean ferritin level (ng/mL) (SD) 693 (420.5) 650 (336.3) 797.4 (579.5)
Patients with ferritin >200 ng/mL (%) 44 (91.7) 32 (94) 12 (85.7)
Patients with recoded TSAT (%) 52 (59.8) 7 (18.4) 45 (91.8)
Mean TSAT % (SD) 38.5 (20) 25.1 (18.7) 40.6 (19)
Patients with TSAT >20% (%) 46 (88.5) 3 (42.9) 43 (95.6)
Patients with ferritin and TSAT recorded (%) 19 (21.8) 7(18.4) 12 (24.5)
Patient with ferritin >200 ng/mL and TSAT >20% (%) 12 (63.2) 3 (42.9) 9 (75)
KKUH=King Khalid University Hospital, PSCKD= Prince Salman Centre for Kidney Disease.
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Figure 4 Iron status by mean Hgb level.
Table 4 Comparision of mean Hgb level by selected patient
characteristicsa.
Characteristics Mean HB G/DL (SD) p-Value
Sex
Female (n= 38) 10.95 (0.74) 0.04
Male (n= 49) 11.41 (1.17)
Age
18–44 (n= 31) 11.3 (0.91) 0.514
45–65 (n= 41) 11.0 (1.0)
P65 (n= 15) 11.3 (0.96)
Albumin
<36 g/L (n= 58) 11.04 (0.85) 0.016
>36 g/L (n= 20) 11.61 (1.07)
IV iron supplement
No (n= 16) 11.07 (0.92) 0.688
Yes (n= 71) 11.17 (0.99)
Duration of dialysis (year)
0.5–0.99 (n= 20) 11.1(0.70) 0.584
1–1.99 (n= 31) 11 (1.2)
>2 (n= 36) 11.3 (0.86)
ACEI or/and ARB usage
No (n= 66) 11.26 (0.95) 0.453
ACEI (n= 5) 10.85 (0.4)
ARB (n= 10) 10.9 (1.44)
Both (n= 5) 10.75 (0.57)
a Comparison with each category was made using t-test or anal-
ysis of variance.
Appropriateness of anemia management in hemodialysis patients 89at risk of iron deﬁciency owing to inappropriate withdrawal of
IV iron therapy. In our study both indices values were avail-
able for only 19 patients and of them 12 have an optimal iron
status (Table 3).
As shown in Figs. 3 and 4 the erythropoietin dosage re-
quired to achieve anemia correction varies among our pa-
tients with patients with Hgb <9 g/dL receiving the highest
dose of erythropoietin. Hyporesponsiveness to erythropoietin
is a probable cause for the low hemoglobin level observed in
some of our patients. KDOQI guidelines (National Kidney
Foundation, 2007) deﬁned the hyporesponsiveness to erythro-
poietin as the presence of at least one of the following: a sig-
niﬁcant increase in the erythropoietin dose requirement is
needed to maintain a certain Hgb level, a signiﬁcant decrease
in Hgb level despite a constant erythropoietin dose, or failure
to increase the Hgb level to greater than 11 g/dL despite an
erythropoietin dose equivalent to erythropoietin greater than
500 IU/kg/Week. Several factors are associated with hypore-
sponsiveness to erythropoietin including iron deﬁciency,
chronic blood loss, inﬂammation/infection, vitamin deﬁcien-
cies, inadequate dialysis, hyperparathyroidism and malig-
nancy (Kalantar-Zadeh et al., 2009; Rossert et al., 2007).
Patients with inadequate response rate to erythropoietin
should undergo evaluation to identify possible causes of
hyporesponse to erythropoietin and iron therapy. However,
this may not be always the case in practice. A survey by
the Saudi Center for Organ Transplant (SCOT) on physi-
cians’ attitudes towards strategies for the treatment of anemia
in patients with CKD found that 86% (115/134) would inves-
tigate the cause of inadequate response rate to erythropoietin;
90 N.A. Al-Ageel et al.however, 10% would increase the dose without further inves-
tigation of the causes of inadequate response (Souqiyyeh and
Shaheen, 2007).
The percentage of patients with elevated Hgb concentra-
tions (>12 g/dL) is lower in our study compared to GSAM
(15% vs 38%). Other studies also reported a good proportion
of hemodialysis patients with Hgb level >12 g/dL (Jacobs
et al., 2005; Locatelli et al., 2004; Collins et al., 2005; Franken-
ﬁeld and Johnson, 2002). A number of publications questioned
the beneﬁcial effects of targeting Hgb levels in excess of
12.0 g/dL (Pharommintikul et al., 2007; Singh et al., 2006;
Drueke et al., 2006; Ritz et al., 2007; Pfeffer et al., 2009). A
meta-analysis of nine randomized controlled trials that en-
rolled 5143 chronic kidney disease patients found a signiﬁ-
cantly higher risk of all-cause mortality (risk ratio 1.17, 95%
CI 1.01–1.35; p= 0.031) arteriovenous access thrombosis
(risk ratio 1.34, 95% CI 1.16–1.54; p= 0.0001), and poorly
controlled blood pressure (risk ratio 1.27, 95% CI 1.08–1.50;
p= 0.004) in the higher Hgb target group (12–16 g/dL) than
in the lower hemoglobin target group (9–12 g/dL) (Phar-
ommintikul et al., 2007). One possible explanation could be
that dialysis patients are able to tolerate anemia at a higher de-
gree than what would be expected and many dialysis-related
factors make the delivery of oxygen to the tissues easier (Hertig
and Ferrer-Marin, 2011). Other evidence also suggest that tar-
geting hemoglobin levels in excess of 12.0 g/dL leads to small
and not clinically meaningful improvements in the health re-
lated quality of life of the dialysis patients (Clement et al.,
2009; Soni et al., 2010) and not cost effective (Tonelli et al.,
2003). In consideration of these ﬁndings the management of
anemia in the ESRD population should aim at a target Hb
no higher than 10–12 g/dL.
An American study (Frankenﬁeld and Johnson, 2002)
involving 8157 hemodialysis patients found that females,
blacks, patients 18–11 years old, and patients receiving hemod-
ialysis for less than six months exhibit signiﬁcantly lower
hemoglobin values despite being prescribed on average, signif-
icantly higher erythropoietin doses than males, whites, older
patients, and patients receiving hemodialysis for six months
or more. The same study found an association between serum
albumin values and prescription of IV iron and Hg values
>11 g/dL. Our results show that being female and having
low serum albumin concentration appears to be associated
with suboptimal serum albumin concentrations (Table 4).
However, our results should be interpreted with caution be-
cause of the small sample size.
There are some limitations to this study. The data collected
from manual recorded patients’ medical records and thus some
information was missing. Several factors inﬂuencing hemoglo-
bin values such as the presence of infection, inﬂammatory
states, blood loss, and parathyroid hormone values were not
evaluated. The small sample size is another limitation. Accord-
ing to SCOT there are 176 dialysis centers in Saudi Arabia
catering for 10,928 patients (Anonymous, 2010). We need lar-
ger studies involving a representative sample of these centers to
understand fully anemia management practices in Saudi
Arabia. We need also adequately powered studies to investi-
gate predictors of suboptimal anemia managements. The qual-
ity of life is an under researched area in Saudi Arabia and we
need such local evidence to compare alternative strategies
effectiveness.In conclusion, there is opportunity to improve anemia man-
agement in hemodialysis patients particularly thorough evalu-
ation of correctable causes of inadequate response rate and
better monitoring and management of iron status.
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